|Go to market news section|
Sinclair IS Pharma plc
Multi product licence and distribution agreement with Menarini Group in Italy, Spain and Central America
LONDON - February 12, 2013 - Sinclair IS Pharma (AIM:SPH.L) ("Sinclair IS"), the international speciality pharma company, announces a multi-product licence and distribution agreement with Menarini Group. This builds on the strong existing relationship with Menarini across Asia Pacific. Menarini will distribute by co-marketing under licensing agreement our products the Kelo franchise, Atopiclair, and Decapinol in Spain and Central America, and Atopiclair in Italy.
"This deal extends and broadens our successful partnership with Menarini in Asia Pacific," said Chris Spooner, Chief Executive Officer, Sinclair IS. "It will give Sinclair IS the opportunity to enhance its sales growth through the co-marketing of several products with a key player in Europe and Central America."
"This deal represents an opportunity to extend in Europe and Central America the successful case history of Asia," said by Maurizio Luongo, OTC Business Unit Director, Menarini "It will reinforce the OTC global portfolio of Menarini Group, following the Mission Statement behind our OTC strategy at international level".
For further information please contact:
Sinclair IS Pharma plc Tel: +44 (0) 20 7467 6920
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
Notes to Editors:
About Sinclair IS Pharma plc - www.sinclairispharma.com
Sinclair IS Pharma is an international specialty pharmaceutical company centred on Dermatology; in particular Aesthetics, Wound care, and Skin care. The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.
About Menarini Group- www.menarini.com
The Menarini Group is the leading Italian pharmaceutical company in the world with a turnover of over €3 billion, 17th in Europe and 34th in the world (IMS World Review 2011). It is present with its own products in over 100 countries in Europe, Asia, Africa, Australia and Latin America with a total employee count of over 16,000. Menarini was established 127 years ago and today is present in most major therapeutic areas. Menarini has always pursued two strategic objectives: research and internationalization. Both have given the company excellent results on the world market making it thus possible to invest in the research of innovative drugs for patients all over the world.
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.
|©London Stock Exchange plc. All rights reserved|